Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC
NCT05626569
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Esophageal Squamous Cell Carcinoma
Oligometastatic Disease
Interventions
DRUG:
PD-1 combined with SBRT
Sponsor
Sun Yat-sen University